Page last updated: 2024-09-05

dofequidar and docetaxel anhydrous

dofequidar has been researched along with docetaxel anhydrous in 2 studies

Compound Research Comparison

Studies (dofequidar)	Trials (dofequidar)	Recent Studies (post-2010) (dofequidar)	Studies (docetaxel anhydrous)	Trials (docetaxel anhydrous)	Recent Studies (post-2010) (docetaxel anhydrous)
40	2	5	12,110	3,216	6,920

Protein Interaction Comparison

Protein	Taxonomy	dofequidar (IC50)	docetaxel anhydrous (IC50)
Kinesin-like protein KIF11	Homo sapiens (human)		0.0014
Nucleotide-binding oligomerization domain-containing protein 2	Homo sapiens (human)		5.0119

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Hirata, H; Matsuba, Y; Naito, M; Sato, S; Tsuruo, T	1
Bonneterre, J; Bonneterre, ME; Degardin, M; Diéras, V; Fumoleau, P; Lacombe, D; Laurence, V; Marreaud, S; Pierga, JY	1

Trials

1 trial(s) available for dofequidar and docetaxel anhydrous

Article	Year
Phase I combining a P-glycoprotein inhibitor, MS209, in combination with docetaxel in patients with advanced malignancies. Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Sep-01, Volume: 11, Issue:17 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B, Member 1; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Prospective Studies; Quinolines; Taxoids; Treatment Outcome	2005

Article

Year

Phase I combining a P-glycoprotein inhibitor, MS209, in combination with docetaxel in patients with advanced malignancies.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Sep-01, Volume: 11, Issue:17

Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B, Member 1; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Prospective Studies; Quinolines; Taxoids; Treatment Outcome

2005

Other Studies

1 other study(ies) available for dofequidar and docetaxel anhydrous

Article	Year
MS-209, a quinoline-type reversal agent, potentiates antitumor efficacy of docetaxel in multidrug-resistant solid tumor xenograft models. Clinical cancer research : an official journal of the American Association for Cancer Research, 2002, Volume: 8, Issue:2 Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Cycle; Cell Division; Cell Line; Docetaxel; Drug Resistance, Neoplasm; Female; Flow Cytometry; Humans; Inhibitory Concentration 50; Maximum Tolerated Dose; Mice; Mice, Inbred BALB C; Mitosis; Models, Chemical; Neoplasm Transplantation; Paclitaxel; Quinolines; Reverse Transcriptase Polymerase Chain Reaction; Taxoids; Time Factors; Tumor Cells, Cultured	2002

Article

Year

MS-209, a quinoline-type reversal agent, potentiates antitumor efficacy of docetaxel in multidrug-resistant solid tumor xenograft models.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2002, Volume: 8, Issue:2

Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Cycle; Cell Division; Cell Line; Docetaxel; Drug Resistance, Neoplasm; Female; Flow Cytometry; Humans; Inhibitory Concentration 50; Maximum Tolerated Dose; Mice; Mice, Inbred BALB C; Mitosis; Models, Chemical; Neoplasm Transplantation; Paclitaxel; Quinolines; Reverse Transcriptase Polymerase Chain Reaction; Taxoids; Time Factors; Tumor Cells, Cultured

2002